Compare · ARGX vs ENGN
ARGX vs ENGN
Side-by-side comparison of argenx SE (ARGX) and enGene Therapeutics Inc. (ENGN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARGX and ENGN operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- ARGX is the larger of the two at $53.41B, about 438.1x ENGN ($121.9M).
- Over the past year, ARGX is up 52.1% and ENGN is down 52.0% - ARGX leads by 104.0 points.
- ENGN has been more active in the news (4 items in the past 4 weeks vs 1 for ARGX).
- ARGX has more recent analyst coverage (25 ratings vs 23 for ENGN).
- Company
- argenx SE
- enGene Therapeutics Inc.
- Price
- $861.30+0.30%
- $1.83-4.69%
- Market cap
- $53.41B
- $121.9M
- 1M return
- -1.91%
- +4.27%
- 1Y return
- +52.05%
- -51.97%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2017
- News (4w)
- 1
- 4
- Recent ratings
- 25
- 23
argenx SE
argenx SE, a clinical-stage biotechnology company, focuses on developing antibody-based therapies for the treatment of autoimmune diseases, hematology, and cancer. It is developing its lead product candidate, efgartigimod, for the treatment of patients with myasthenia gravis; immune thrombocytopenia in Phase III; pemphigus vulgaris in Phase III; chronic inflammatory demyelinating polyneuropathy in Phase III; and ENHANZE SC in pre-clinical stages. The company is also developing cusatuzumab in Phase II clinical stage in hematological cancer indications; ARGX-117 in phase I clinical trial with therapeutic potential in both orphan and large autoimmune inflammatory diseases; and preclinical products, including ARGX-118 for airway inflammation. Its partnered product candidates include ARGX-112 for treating skin inflammation, ARGX-116 for the treatment of dyslipidemia, and ARGX-115 for cancer immunotherapy, which are in Phase I clinical stages; and ARGX-114 for treating fibrosisand ARGX-119 for treating neuromuscular indications, which are in preclinical stage. The company has strategic partnership with AbbVie S.Ã.R.L. and LEO Pharma A/S; and collaboration agreement with Cilag GmbH International, Staten Biotechnology B.V., and Shire International GmbH. argenx SE was incorporated in 2008 and is based in Breda, the Netherlands.
Latest ARGX
- argenx to Report Half Year 2026 Financial Results and Second Quarter Business Update on July 23, 2026
- SEC Form 6-K filed by argenx SE
- argenx to Host Autoimmune Myositis R&D Webinar
- SEC Form 6-K filed by argenx SE
- argenx Presents New Efgartigimod Data Showing Long-Term Sustained Patient Benefit in Myositis and Sjogren's Disease at EULAR 2026
- argenx to Host Myositis R&D Webinar on June 23, 2026
- argenx to Present at Upcoming Investor Conferences
- The Biology Came First.
- SEC Form 6-K filed by argenx SE
- argenx Announces U.S. FDA Approval Expanding VYVGART and VYVGART Hytrulo for Use in All Adult Patients Living with gMG
Latest ENGN
- enGene Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- enGene Therapeutics Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones
- Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman
- Amendment: enGene Therapeutics Inc. filed SEC Form 8-K: Costs Associated with Exit or Disposal Activities, Leadership Update
- enGene Therapeutics downgraded by Morgan Stanley
- SEC Form 4 filed by Director Astley-Sparke Philip
- SEC Form 4 filed by Director Brunk Gerald A
- SEC Form 4 filed by Director Glickman Richard M
- SEC Form 4 filed by Interim Chief Medical Officer Grossman William